Pill Identifier App

Generic Sandostatin Availability

Sandostatin is a brand name of octreotide, approved by the FDA in the following formulation(s):

SANDOSTATIN (octreotide acetate - injectable;injection)

  • Manufacturer: NOVARTIS
    Approval date: October 21, 1988
    Strength(s): EQ 0.05MG BASE/ML [RLD] [AP], EQ 0.1MG BASE/ML [RLD] [AP], EQ 0.5MG BASE/ML [RLD] [AP]
  • Manufacturer: NOVARTIS
    Approval date: June 12, 1991
    Strength(s): EQ 0.2MG BASE/ML [RLD] [AP], EQ 1MG BASE/ML [RLD] [AP]

Has a generic version of Sandostatin been approved?

A generic version of Sandostatin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Sandostatin and have been approved by the FDA:

octreotide acetate injectable;injection

  • Manufacturer: FRESENIUS KABI USA
    Approval date: February 10, 2006
    Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
  • Manufacturer: SAGENT PHARMS
    Approval date: November 12, 2013
    Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
  • Manufacturer: SUN PHARM INDS
    Approval date: August 14, 2007
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.2MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
  • Manufacturer: SUN PHARM INDS
    Approval date: March 4, 2008
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.2MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
  • Manufacturer: TEVA PHARMS USA
    Approval date: October 3, 2005
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
  • Manufacturer: TEVA PHARMS USA
    Approval date: November 21, 2005
    Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]
  • Manufacturer: WOCKHARDT USA
    Approval date: May 11, 2011
    Strength(s): EQ 0.2MG BASE/ML [AP], EQ 1MG BASE/ML [AP]

OCTREOTIDE ACETATE (PRESERVATIVE FREE) (octreotide acetate injectable;injection)

  • Manufacturer: FRESENIUS KABI USA
    Approval date: February 10, 2006
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
  • Manufacturer: MYLAN INSTITUTIONAL
    Approval date: February 10, 2011
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
  • Manufacturer: SAGENT PHARMS
    Approval date: November 12, 2013
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]
  • Manufacturer: WOCKHARDT USA
    Approval date: May 11, 2011
    Strength(s): EQ 0.05MG BASE/ML [AP], EQ 0.1MG BASE/ML [AP], EQ 0.5MG BASE/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sandostatin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Somatostatin analogue composition and use in treating breast cancer
    Patent 5,753,618
    Issued: May 19, 1998
    Inventor(s): Cavanak; Thomas & Harris; Alan
    Assignee(s): Novartis Corporation
    The invention provides a pharmaceutical composition containing a somatostatin analogue, and its use in the treatment of breast cancer. The pharmaceutical composition preferably contains lactic acid in addition to the somatostatin analogue and is better tolerated when administered by injection.
    Patent expiration dates:
    • May 19, 2015
    • November 19, 2015
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide
(web1)